- iBio (NYSE:IBIO +6.8%) enters into a $10M common stock purchase agreement with Aspire Capital Fund LLC. After its initial purchase of 1,136,354 shares at $0.44 per share, Aspire has committed to buying up to $9.5M in additional shares of common stock over a 24-month period.
- Proceeds will help fund clinical trials of its biotherapeutic product candidate for the treatment of fibrosis, which are slated to begin in early 2015.